Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma

Human Pathology, 03/29/2012

The results suggest that the combination of BRAF and NRAS mutation analysis with fusion gene detection contributes to diagnosis of malignant melanoma and clear cell sarcoma, and that insulin–like growth factor 1R might be a novel target for the treatment of these two malignancies.

Print Article Summary Cat 2 CME Report